Biotech | January 03, 2022
Novavax submits data to U.S. FDA for Covid-19 EUA
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Emergency Use Authorisation application request to be submitted following one month required by FDA EUA guidance
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
The company will market it under the brand name Molflu
The Home Healthcare market is expected to be US $ 14.2 by 2025
SK bioscience secures long-term license to supply the Novavax vaccine for the Korean market
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Subscribe To Our Newsletter & Stay Updated
